OMN 54

Drug Profile

OMN 54

Alternative Names: Aneustat; OMN54

Latest Information Update: 10 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genyous Biomed
  • Class Antineoplastics
  • Mechanism of Action Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 09 Nov 2015 Final adverse events, pharmacokinetics and efficacy data from a phase I trial presented by Omnitura at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015
  • 20 Aug 2012 Phase-I clinical trials in Lymphoma in Canada (PO)
  • 20 Aug 2012 Phase-I clinical trials in Solid tumours in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top